The Comparison of the Pharmacokinetic, Safety and Tolerability of Alpha-1 MP and Prolastin In Adult Alpha1-Antitrypsin Deficient Patients (ChAMP)

This study has been completed.

Sponsor:

Information provided by:

Grifols Therapeutics Inc.

ClinicalTrials.gov Identifier:

NCT00295061

First received: February 20, 2006

Last updated: September 26, 2008

Last verified: September 2008

History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Study Completion Date:	February 2007
Estimated Primary Completion Date:	No date given

No publications provided by Grifols Therapeutics Inc.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Stocks JM, Brantly ML, Wang-Smith L, Campos MA, Chapman KR, Kueppers F, Sandhaus RA, Strange C, Turino G. Pharmacokinetic comparability of Prolastin®-C to Prolastin® in alpha?-antitrypsin deficiency: a randomized study. BMC Clin Pharmacol. 2010 Sep 30;10:13.

To Top